Antibody-based formats to target glioblastoma: overcoming barriers to protein drug delivery

Saikat Ghosh, Pie Huda, Nicholas L. Fletcher, Christopher B. Howard, Brad Walsh, Douglas Campbell, Mark B. Pinkham, Kristofer J. Thurecht*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Glioblastoma (GB) is recognized as the most aggressive form of primary brain cancer. Despite advances in treatment strategies that include surgery, radiation, and chemotherapy, the median survival time (∼15 months) of patients with GB has not significantly improved. The poor prognosis of GB is also associated with a very high chance of tumor recurrence (∼90%), and current treatment measures have failed to address the complications associated with this disease. However, targeted therapies enabled through antibody engineering have shown promise in countering GB when used in combination with conventional approaches. Here, we discuss the challenges in conventional as well as future GB therapeutics and highlight some of the known advantages of using targeted biologics to overcome these impediments. We also review a broad range of potential alternative routes that could be used clinically to administer anti-GB biologics to the brain through evasion of its natural barriers.
Original languageEnglish
Pages (from-to)1233-1247
Number of pages15
JournalMolecular Pharmaceutics
Issue number5
Early online date19 Apr 2022
Publication statusPublished - 2 May 2022
Externally publishedYes


  • antibody
  • antibody fragments
  • blood-brain barrier
  • glioblastoma
  • molecular imaging
  • nuclear medicine


Dive into the research topics of 'Antibody-based formats to target glioblastoma: overcoming barriers to protein drug delivery'. Together they form a unique fingerprint.

Cite this